Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study (MONOTREAT)

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: December 10, 2012
Last updated: August 24, 2015
Last verified: August 2015
Patients with advanced Parkinson's Disease experience a range in the severity of their motor fluctuations. The rationale for this Post Marketing Observational Study is to demonstrate the benefits of Duodopa treatment on Parkinson's Disease patients entering the advanced stage of the disease whose motor fluctuations have become troublesome and complicate management with oral therapy. The aim of this post-marketing observational study is to assess the effect of Duodopa treatment on activities of daily living in advanced Parkinson's Disease patients characterised by either 2-4 hours of "off" time or 2 hours of non-troublesome or troublesome dyskinesia daily, supported by a Unified Parkinson's Disease Rating Scale Total Score in the best "on" state of at least 40 points at baseline.

Parkinson's Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Analysis of MOtor and NOn Motor Symptoms, Quality of Life and Occurence of Dyskinesias in Advanced Parkinson's Disease Patients With 2 to 4 Hours 'Off-time' and Without Troublesome Dyskinesias Under Duodopa TREATment - a Multi-country Post-marketing Observational Study -MONOTREAT

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients who continue with PEG-J treatment [ Time Frame: 14 days ] [ Designated as safety issue: No ]
  • UPDRS III, IV (items 32, 33, 34, 39) [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Non-Motor Symptoms Scale [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Parkinson's Disease Quality of Life Questionnaire [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
  • Healthcare Resource Utilization [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

Enrollment: 64
Study Start Date: February 2013
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Patients given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy
Standard of care
Patients that return to oral or transdermal anti-parkinson's disease medications

Detailed Description:

Data are recorded from visits most closely aligned with the planned periods of Visit 0 (V0): Baseline (After decision to use the temporary naso-duodenal tube (approximately 2-14 days) and after signature of the Patient Authorization/ICF); Visit 1 (V1): At discharge from hospital; Visit 2 (V2): 3 months after discharge; Visit 3 (V3): 6 months after discharge; Visit 4 (V4): 12 months after discharge.

All patients have a temporary naso-duodenal tube used initially with the infusion pump to determine if the subject responds favorably to this method of treatment and to optimize the dose of Duodopa before permanent treatment is started.

Patients who choose a treatment other than Duodopa after the temporary naso-duodenal test phase are considered for the Standard of Care group. Patients who go on to select Apomorphine pump or Deep Brain Stimulation at any stage are not eligible to continue in this group or to continue in the observational period of study.

Patients who continue to with Duodopa treatment after the the temporary naso-duodenal test phase are the Duodopa group.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital clinic

Inclusion Criteria:

  • Has advanced levodopa-responsive Parkinson's disease
  • The decision to treat with Duodopa is made by the physician in accordance with the local label (Summary of Product Characteristics; product label) prior to any decision to approach the patient to participate in this study
  • Parkinson's Disease (PD) medicinal treatment is unchanged for at least four weeks prior to baseline
  • Takes oral medication four or more times daily
  • Either has 2-4 hours of "off" time or 2 hours of non-troublesome or troublesome dyskinesia daily supported by a Unified Parkinson's Disease Rating Scale (UPDRS) Total Score in the best "on" state of at least 40 points at baseline; based on documented medical history

Exclusion Criteria:

  • Use of Deep Brain Stimulation (DBS), Apomorphine pump or Duodopa treatment prior to baseline visit
  • Severe dementia based on a Mini-Mental State Examination (MMSE) of < 24
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01747655

Site Reference ID/Investigator# 88055
Graz, Austria, 8036
Site Reference ID/Investigator# 124479
Hermagor, Austria, 9620
Site Reference ID/Investigator# 92996
Aarhus C, Denmark, 8000
Site Reference ID/Investigator# 90173
Freiburg, Germany, 79106
Site Reference ID/Investigator# 90195
Goettingen, Germany, 37075
Site Reference ID/Investigator# 96715
Jena, Germany, 07743
Site Reference ID/Investigator# 96636
Kaiserslautern, Germany, 67655
Site Reference ID/Investigator# 89273
Tuebingen, Germany, 72076
Site Reference ID/Investigator# 90197
Ulm, Germany, 89081
Site Reference ID/Investigator# 89573
Athens, Greece, 11521
Site Reference ID/Investigator# 89574
Athens, Greece, 11525
Site Reference ID/Investigator# 90154
Cagliari-CA, Italy, 09134
Site Reference ID/Investigator# 109855
Mestre, Italy
Site Reference ID/Investigator# 90155
Pesaro (PU), Italy, 61121
Site Reference ID/Investigator# 90159
Rome, Italy, 00133
Site Reference ID/Investigator# 90157
Savigliano, Italy
Site Reference ID/Investigator# 109175
Woerden, Netherlands, 3447 GN
Site Reference ID/Investigator# 93773
Zwolle, Netherlands, 8011 JW
Site Reference ID/Investigator# 112155
Barcelona, Spain, 08035
Site Reference ID/Investigator# 87313
Bilbao, Spain, 48903
Site Reference ID/Investigator# 88133
L'Hospitalet de Llobregat, Spain, 8907
Site Reference ID/Investigator# 87294
Madrid, Spain, 28034
Site Reference ID/Investigator# 102035
Palma de Mallorca, Balearas, Spain, 07010
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Koray Onuk, MD AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT01747655     History of Changes
Other Study ID Numbers: P13-893 
Study First Received: December 10, 2012
Last Updated: August 24, 2015
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios
Italy: The Italian Medicines Agency
Austria: Agency for Health and Food Safety
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AbbVie:
Parkinson's Disease
Early Observational Advanced

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Carbidopa, levodopa drug combination
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 23, 2016